William has over 30 years of experience in the Pharmaceutical, Biotechnology and Diagnostic sectors encompassing SME and multi-national corporations. He has worked at senior vice president level covering Europe, USA, Latin America, Asia Pacific and Japan. William has completed a wide range of entrepreneurial projects including management buyouts, business turnarounds, trade sales and the securing of investments in the Biotech sector.
Professor of Cell Biology and Director of the Institute of Cardiovascular and Metabolic Research, University of Reading
Jon is an internationally acclaimed academic researcher in the field of platelet biology and translational research, and has contributed extensively to the discovery of key mechanisms of platelet regulation in health and disease. He has collaborated and published papers extensively with colleagues globally and served as founder and chair of the Platelet Society. Having authored over 200 research papers, Jon's 30 years of dedicated platelet research have culminated in the establishment of HaemAnalytica, driven by his unwavering commitment to advancing cardiovascular health.
Associate professor of Thrombosis and Haemostasis, University of Reading
Chris is a globally recognized scientist in the field of platelet function and signalling.
His groundbreaking research forms the cornerstone of HaemAnalytica, providing extensive expertise in measuring platelets in large cohorts and clinical studies. This has resulted in a profound understanding of patient phenotyping through AI and has laid the groundwork for improving platelet services leading to personalized medicine.
Gemma started developing point-of-care devices to measure platelet function after completing her undergraduate degree in Biomedical Sciences, before completing her PhD investigating the role of HSP47 on platelets and their precursor, megakaryocytes. She is experienced in platelet function analysis, advanced microscopy techniques, and cell based assays. Gemma has worked with HaemAnalytica technologies since their development in the lab during her PhD and will use her scientific background to ensure HaemAnalytica products and services align with market needs.
Jeremy has held CEO/COO/board positions with both private and public multinational companies in the UK, UAE, Brazil, the Philippines, Hong Kong and New Zealand. His business experience includes, business development, international investments, mergers, acquisitions and company divestments, turnarounds, leveraged management buyouts and startups.
Jenny has 25 years experience in clinical development across multiple regions (EU/UK/Switzerland, US/Canada, South America, Asia-Pacific), in the Biotechnology and Pharmaceutical sector. She has held leadership roles driving clinical strategy at a product level and oversight of clinical operations at a functional level, ensuring efficient clinical study execution combined with process improvement. With broad exposure across modalities and indications, her therapeutic experience includes running large, multi-region clinical trials in cardiovascular indications, clinical testing of t-cell therapies involving innovative biomarker testing and development of companion diagnostics.
Neil has over 20 years experience as a clinician and 8 years a Consultant Interventional and General Cardiologist. He completed his medical degree from University College London and a DPhil (PhD) from the University of Oxford. His clinic training encompassed fellowships in London, Oxford, Milan, Italy and Boston, USA. He is the author of over 150 publications in all areas of basic and clinical cardiovascular science. He currently works clinically between the Hammersmith Hospital, London and the Royal Berkshire Hospital, Reading and is Professor of Cardiovascular Medicine at the University of Reading and Honorary Clinical Senior Lecturer at Imperial College, London.
Nichola Cooper is Professor of Immune Haematology at Imperial London University and Honorary Consultant Haematologist at Imperial Health Care NHS Trust, London, UK. She completed her undergraduate degrees at Cambridge University and Barts and the London Hospital Medical College, University of London, UK. She also holds further research degrees from Cornell Medical School, New York Presbyterian Hospital, USA.
Professor Cooper now runs a phase 1, 2 and 3 clinical trials program in ITP and a laboratory research programme investigating the genetic and environmental causes of haematological autoimmunity. She has authored many papers published in international, peer-reviewed journals including Nature, Science, Nature Immunology, NEJM and Blood.
Registered in England, company number 15921838
Web design by Tribal Systems